Ifinatamab deruxtecan for advanced small cell lung cancer after prior treatments
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This program tests a new drug called ifinatamab deruxtecan for people with extensive-stage small cell lung cancer that has progressed after at least two prior treatments. The drug is designed to target and attack cancer cells while potentially limiting damage to healthy cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have extensive-stage small cell lung cancer confirmed by biopsy or cytology.
- You must have had at least two prior lines of systemic therapy, including platinum-based chemotherapy.
- Your cancer must have worsened after your most recent treatment, as shown by imaging.
- You must be in good enough physical condition to carry out daily activities (ECOG 0-1), with a life expectancy of at least 3 months.
- You must have adequate organ and bone marrow function, and no untreated or symptomatic brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (I-DXd and atezolizumab, with or without carboplatin) as your first treatment for extensive stage small cell lung cancer. It has two groups: one for people who haven't started treatment yet, and another for those who've already had 4 cycles of a standard chemo-immunotherapy combination and are stable or better.
This trial tests a combination of three drugs (adebrelimab, irinotecan liposome, and famitinib) for people with extensive-stage small cell lung cancer whose disease got worse after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two drugs (irinotecan liposome and ivonescimab) for people with advanced small cell lung cancer whose first treatment (chemotherapy with or without immunotherapy) stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.